2023-10-02 07:32:00
After its widespread use, and after gaining widespread fame for its clear results in weight loss, the US Food and Drug Administration (FDA) decided to update the label for the diabetes drug “Ozambik” and acknowledge reports of cases of intestinal obstruction among some of its users.
This drug, which is usually used to treat diabetes, has today turned into a weight-loss drug, as many people resorted to using it with the aim of losing weight after achieving promising results. The drug “Ozempic” and its counterpart, “Wegovy”, have become widely popular recently, and both are approved for weight loss.
In a statement to CNN, Novo Nordisk, the pharmaceutical company that manufactures Ozambik and the similar drug Wijovi, said that patient safety is a top priority and that it works closely with the Food and Drug Administration to “continuously monitor the safety profile” of its drugs.
The labels for Wijovi and the diabetes drug Monjaro indicate reports of a condition called ileus (intestinal obstruction) in some of their users, which prompted the Ozambic label to be updated to indicate the same.
How does the medicine work?
Ozambik and Wijovi use a drug called semaglutide, which is part of a family of medications known as GLP-1 agonists that work by mimicking a hormone the body naturally makes to slow the passage of food through the stomach, which helps you feel full for a while. Longer.
Poster update
Returning to the label, it is stated that “because these reactions are reported voluntarily by a population of unknown size, it is not always possible to reliably estimate their frequency, or establish a causal relationship with drug exposure.”
Some people using Ozempic and Wijovi have also reported developing a condition called gastroparesis.
Experts believe that these cases are rare, and may not be a direct result of consuming the medications themselves.
In response to these allegations, Novo Nordisk told CNN last June that “GLP1 agonists have been studied extensively and have been used for years.
The company explained in a statement: “For semaglutide, the majority of gastrointestinal side effects are mild to moderate in severity and short in duration.
GLP1 is also known to delay gastric emptying, as stated on the label of each of our GLP-1 RA medications. Symptoms of delayed gastric emptying, nausea, and vomiting are listed as side effects.”
It is noteworthy that a woman from the US state of Louisiana has filed a lawsuit against Novo Nordisk and Eli Lilly over what she claims are “serious gastrointestinal events” that she suffered as a result of using the drugs “Ozambik” and “Monjaro.”
1696249451
#Reports #intestinal #obstruction #updating #labels #popular #weight #loss #drug #Ozempic